Affimed NV (LTS:0HL9)
$ 2.22 0.1082 (4.73%) Market Cap: 38.03 Mil Enterprise Value: 25.31 Mil PE Ratio: 0 PB Ratio: 1.99 GF Score: 26/100

Q2 2022 Affimed NV Earnings Call Transcript

Aug 11, 2022 / 12:30PM GMT
Release Date Price: $31.8 (+0.47%)
Operator

Good day, everyone, and welcome to the Affimed Second Quarter 2022 Financial Results and Corporate Update Conference Call. My name is Vanessa, and I will be your operator for today's call.

(Operator Instructions) As a reminder, this conference is being recorded.

I would now like to introduce your host for today's call, Mr. Alex Fudukidis, Head of Investor Relations at Affimed. Sir, you may begin.

Alexander Fudukidis
Affimed N.V. - Head of IR

Thank you, Vanessa, and thank you all for joining us today for our call.

Before we begin, I'd like to remind everyone that we issued the relevant press release earlier today, which can be found on the Investor Relations section of our website.

On the call today, we have members of our management team, including Adi Hoess, our Chief Executive Officer; Andreas Harstrick, our Chief Medical Officer; Arndt Schottelius, our Chief Scientific Officer; Denise Mueller, our Chief Business Officer; and Angus Smith, our Chief Financial Officer. The team will be available for the Q&A session

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot